CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The U.K. and EU have pre-ordered up to 455 million doses of CureVac's mRNA vaccine, subject to regulatory approval.

Covid vaccine maker CureVac hopes shot will get EU approval in June

CureVac BV (NASDAQ: CVAC) has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV. The commercial supply agreement includes manufacturing of the mRNA drug substance and LNP formulation of the bulk drug product at Celonic's manufacturing facility in Heidelberg, Germany.

CureVac Taps Celonic For COVID-19 Vaccine Production

First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with virus variant neutralizing capacity in immunized animals Full protection of immunized mice from infection and mortality during variant challenge infection TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 23, 2021 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the "South African" variant) and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

CureVac BV (NASDAQ: CVAC) plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America.

CureVac Expands Late-Stage Trials Of COVID-19 Vaccine Candidate

Moderna

Pfizer

AstraZeneca

BioNTech SE

Johnson & Johnson

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Novartis

Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.

Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine

Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecules that the vaccine is based on and “bulk drug product” for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022.

Novartis Lends Support To Manufacture CureVac's COVID-19 Shots

Novartis AG and CureVac NV said Thursday they have reached an agreement for Novartis to help CureVac manufacture its COVID-19 vaccine, which is currently under review by the European Medicines Agency. Novartis expects to make up to 50 million doses of the vaccine by the end of 2021, and up to a further 200 million doses in 2022, at its manufacturing site in Kundl, Austria.

Novartis agrees to help make CureVac COVID-19 vaccine

Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session.  US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the two companies that have received  emergency use authorization for vaccine candidates in the U.S., confirmed supply deals with the federal government.

COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine

Shares of CureVac gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine is currently being tested in a Phase 3 clinical trial in Europe and Latin America.

CureVac's stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.

The UK government has said it is to join forces with German group CureVac BV (NASDAQ:CVAC) to develop vaccines capable of dealing with mutations in the coronavirus (COVID-19) virus. Britain has initially ordered 50mln doses of any vaccine developed through the collaboration, which will see the company work with the UK Vaccine's Taskforce.

UK Government teams up with CureVac to find mutant COVID-19 vaccine

The U.K. has entered into a collaboration accord with CureVac NV (NASDAQ: CVAC) to develop messenger ribonucleic acid (mRNA)-based vaccine candidates against COVID-19 variants.  CureVac will deliver an initial supply of 50 million doses of any resulting vaccine candidates.

CureVac Shares Gain After UK Backs Company's Vaccine Development Efforts For COVID-19 Variants

Shares of CureVac gained 7.7% in trading on Friday after the company said it plans to develop COVID-19 vaccine candidates that can prevent infection with new variants as part of an agreement with the United Kingdom. The U.K. has already agreed to take 50 million doses of the yet-to-be-identified variant vaccines.

CureVac to develop new variant vaccines for the U.K.

CureVac N.V. (NASDAQ: CVAC) has expanded its ongoing Phase 1 study with its lead RNA-based cancer drug candidate, CV8102, intending to confirm safety, tolerability, and efficacy of CV8102 in patients with advanced melanoma at 600µg, the selected dose to be advanced in Phase 2 trial.

CureVac Expands Early-Stage Study Evaluating CV8102 In Skin Cancer

GlaxoSmithKline

UK pharma giant GlaxoSmithKline (GSK) and German biotech CureVac plan to co-develop "next generation" vaccines that could work against multiple coronavirus variants at once, the companies announced Wednesday. The vaccines could be available in 2022, subject to authorization, and could work as a booster if immunity from another vaccine wanes, or for people who haven't yet been immunized, the companies said.

GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once

U.K.-based GlaxoSmithKline Plc (NYSE: GSK) and Germany's CureVac BV (NASDAQ: CVAC) have announced to work together in a €150 million collaboration for the development of a new generation of COVID-19 vaccines to tackle emerging variants of the virus.

GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants

GSK and CureVac said their approach could potentially tackle multiple coronavirus strains in one vaccine shot

GSK and CureVac join forces to develop vaccines targeting new COVID-19 variants

Shares of CureVac were down 3.1% in premarket trading on Thursday after the German company said it aims to raise $450 million through a follow-up public offering. CureVac, which went public in August, priced the follow-on public offering of 5 million shares at $90.00 per common share.

CureVac aims to raise $450 million through public offering

CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation of an approval for its COVID-19 vaccine.

CureVac: Smart Money Is On COVID-19 Vaccine Approval

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 11, 2021 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates.

CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Bayer AG

CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.

CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine

The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.

Why Coronavirus Stock CureVac Crushed It on Thursday

CureVac stock popped in bullish volume Thursday after the company inked a collaboration deal with Bayer for its coronavirus vaccine. They hope to supply millions of doses worldwide.

This Covid Vaccine Stock Just Rocketed On A Deal With Pharma Giant Bayer

Sometimes you need a little help from a big brother.

CureVac Secures Bayer as a Partner for Its Coronavirus Vaccine

CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday it has signed a collaboration and services agreement with German chemicals company Bayer AG (Pink: BAYRY) for the further development, supply and territorial operations of CureVac's CVnCoV.

News for CureVac B.V Stock (CVAC)